Ponatinib Versus Imatinib in Patients with Newly Diagnosed Ph plus ALL: Subgroup Analysis of the Phase 3 Phallcon Study

被引：0

作者：

Aldoss, Ibrahim ^{[1
]}

Ribera, Josep-Maria ^{[2
]}

Kantarjian, Hagop ^{[3
]}

Montesinos, Pau ^{[4
]}

Leonard, Jessica T. ^{[5
]}

Gomez-Almaguer, David ^{[6
]}

Baer, Maria R. ^{[7
]}

Gambacorti-Passerini, Carlo ^{[8
]}

McCloskey, James ^{[9
]}

Minami, Yosuke ^{[10
]}

Papayannidis, Cristina ^{[11
]}

Rocha, Vanderson ^{[12
]}

Rousselot, Philippe ^{[13
]}

Vachhani, Pankit ^{[14
]}

Wang, Eunice S. ^{[15
]}

Hennessy, Meliessa ^{[16
]}

Patel, Niti ^{[16
]}

Vorog, Alexander ^{[16
]}

Wang, Bingxia ^{[16
]}

Jabbour, Elias ^{[17
]}

机构：

[1] City Hope Natl Med Ctr, Duarte, CA USA

[2] Hosp Badalona Germans Trias & Pujol, ICO Badalona, Josep Carreras Leukaemia Res Inst, Badalona, Spain

[3] Univ Texas MD Anderson Canc Ctr, Dept Leukemia, Houston, TX USA

[4] Hosp Univ & Politecn La Fe Valencia, Valencia, Spain

[5] Oregon Hlth & Sci Univ, Portland, OR USA

[6] UANL, Hosp Univ Dr Jose Eleuterio Gonzalez, Monterrey, Mexico

[7] Univ Maryland, Dept Med, Sch Med, Baltimore, MD USA

[8] Univ Milano Bicocca, Monza, Italy

[9] Hackensack Univ, Med Ctr, Hackensack, NJ USA

[10] Natl Canc Ctr Hosp East, Kashiwa, Chiba, Japan

[11] IRCCS Azienda Osped Univ Bologna, Ist Ematol Seragnoli, Bologna, Italy

[12] Univ Sao Paulo, Inst Canc Estado Sao Paulo, Sao Paulo, Brazil

[13] Univ Versailles Paris Saclay, Ctr Hosp Verailles, UMR1184, Versailles, France

[14] Univ Alabama Birmingham, Birmingham, AL USA

[15] Roswell Pk Comprehens Canc Ctr, Buffalo, NY USA

[16] Takeda Dev Ctr Amer Inc, Lexington, MA USA

[17] Univ Texas MD Anderson Canc Ctr, Houston, TX USA

来源：

BLOOD | 2023年 / 142卷

关键词：

D O I：

10.1182/blood-2023-179537

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

引用

页数：5

共 50 条

[1] IN-DEPTH SAFETY ANALYSIS OF PHALLCON: A PHASE 3 STUDY COMPARING PONATINIB VERSUS IMATINIB IN NEWLY DIAGNOSED PH plus ALL
Yee, Sheena
Aldoss, Ibrahim
Hennessy, Meliessa
Vorog, Alexander
Patel, Niti
Jabbour, Elias
ONCOLOGY NURSING FORUM, 2024, 51 (02)
[2] In-depth Responder Analysis of PhALLCON, a Phase 3 Trial of Ponatinib Versus Imatinib in Newly Diagnosed Ph plus ALL
Jabbour, Elias
Kantarjian, Hagop
Aldoss, Ibrahim
Montesinos, Pau
Leonard, Jessica T.
Gomez-Almaguer, David
Baer, Maria R.
Gambacorti-Passerini, Carlo
McCloskey, James
Minami, Yosuke
Papayannidis, Cristina
Rousselot, Philippe
Vachhani, Pankit
Wang, Eunice S.
Yang, Lin
Hennessy, Meliessa
Vorog, Alexander
Patel, Niti
Ribera-Santasusana, Jose-Maria
CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2024, 24 : S268 - S269
[3] Ponatinib Monotherapy after Combination with Chemotherapy in Patients with Newly Diagnosed Ph plus ALL: Post Hoc Subgroup Analysis of the Phase 3 Phallcon Study
Jabbour, Elias
Kantarjian, Hagop M.
Aldoss, Ibrahim
Montesinos, Pau
Leonard, Jessica T.
Gomez-Almaguer, David
Baer, Maria R.
Gambacorti-Passerini, Carlo
Mccloskey, James
Minami, Yosuke
Papayannidis, Cristina
Rocha, Vanderson
Rousselot, Philippe
Vachhani, Pankit
Wang, Eunice S.
Yang, Lin
Hennessy, Meliessa
Vorog, Alexander
Patel, Niti
Yeh, Tammie
Ribera, Josep-Maria
BLOOD, 2024, 144 : 2821 - 2823
[4] In-depth analysis of responders in the phase 3 PhALLCON trial of ponatinib vs imatinib in newly diagnosed Ph plus ALL.
Jabbour, Elias
Kantarjian, Hagop M.
Aldoss, Ibrahim
Montesinos, Pau
Leonard, Jessica Taft
Gomez-Almaguer, David
Baer, Maria R.
Gambacorti-Passerini, Carlo
McCloskey, James K.
Minami, Yosuke
Papayannidis, Cristina
Rousselot, Philippe
Vachhani, Pankit
Wang, Eunice S.
Yang, Lin
Hennessy, Meliessa
Vorog, Alexander
Patel, Niti
Ribera-Santasusana, Jose-Maria
JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
[5] Ponatinib vs Imatinib with Reduced-Intensity Chemotherapy in Patients with Newly Diagnosed Philadelphia Chromosome-Positive (Ph plus ) ALL: PhALLCON Study
Jabbour, Elias
Martinelli, Giovanni
Vignetti, Marco
Ribera, Jose-Maria
Gomez-Almaguer, David
Minami, Yosuke
Xu, Jing
Srivastava, Shouryadeep
Neumann, Frank
Kantarjian, Hagop
CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2019, 19 : S194 - S194
[6] Phase 3 PhALLCON study: Ponatinib (PON) versus imatinib (IM) with reduced-intensity chemotherapy (CT) in patients (pts) with newly diagnosed Philadelphia chromosome positive (Ph plus ) ALL.
Jabbour, Elias
Martinelli, Giovanni
Vignetti, Marco
Ribera, Josep-Maria
Gomez-Almaguer, David
Minami, Yosuke
Xu, Jing
Srivastava, Shouryadeep
Neumann, Frank
Kantarjian, Hagop M.
JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (15)
[7] Ponatinib Versus Imatinib with Reduced-Intensity Chemotherapy in Patients with Newly Diagnosed Philadelphia Chromosome-Positive (Ph plus ) Acute Lymphoblastic Leukemia (ALL): PhALLCON Study
Jabbour, Elias
Martinelli, Giovanni
Vignetti, Marco
Kantarjian, Hagop
Gomez-Almaguer, David
Minami, Yosuke
Dombret, Herve
Hennessy, Meliessa
Vorog, Alexander
Wang, Bingxia
Ribera, Josep-Maria
CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2021, 21 : S269 - S269
[8] First report of PhALLCON: A phase 3 study comparing ponatinib (pon) vs imatinib (im) in newly diagnosed patients with Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph plus ALL).
Jabbour, Elias
Kantarjian, Hagop M.
Aldoss, Ibrahim
Montesinos, Pau
Leonard, Jessica Taft
Gomez-Almaguer, David
Baer, Maria R.
Gambacorti-Passerini, Carlo
McCloskey, James
Minami, Yosuke
Papayannidis, Cristina
Geraldo Rocha, Vanderson
Rousselot, Philippe
Vachhani, Pankit
Wang, Eunice S.
Wang, Bingxia
Hennessy, Meliessa
Vorog, Alexander
Patel, Niti
Ribera, Josep-Maria
JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (36_SUPPL) : 398868 - 398868
[9] First report of PhALLCON: A phase 3 study comparing ponatinib (pon) vs imatinib (im) in newly diagnosed patients with Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph plus ALL).
Jabbour, Elias
Kantarjian, Hagop M.
Aldoss, Ibrahim
Montesinos, Pau
Leonard, Jessica Taft
Gomez-Almaguer, David
Baer, Maria R.
Gambacorti-Passerini, Carlo
McCloskey, James
Minami, Yosuke
Papayannidis, Cristina
Rocha, Vanderson Geraldo
Rousselot, Philippe
Vachhani, Pankit
Wang, Eunice S.
Wang, Bingxia
Hennessy, Meliessa
Vorog, Alexander
Patel, Niti
Ribera, Josep-Maria
JOURNAL OF CLINICAL ONCOLOGY, 2023, 41
[10] First Report of PhALLCON: A Phase 3 Study Comparing Ponatinib Versus Imatinib in Newly Diagnosed Philadelphia Chromosome-Positive Acute Lymphocytic Leukemia
Jabbour, Elias
Kantarjian, Hagop
Aldoss, Ibrahim
Montesinos, Pau
Leonard, Jessica
Gomez-Almaguer, David
Baer, Maria
Gambacorti-Passerini, Carlo
McCloskey, James
Minami, Yosuke
Papayannidis, Cristina
Rocha, Vanderson
Rousselot, Philippe
Vachhani, Pankit
Wang, Eunice
Hennessy, Meliessa
Patel, Niti
Vorog, Alexander
Wang, Bingxia
Yeh, Tammie
Ribera, Jose-Maria
CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2023, 23 : S245 - S245

← 1 2 3 4 5 →